Story time! The Great Unbalding (PP405)
    10/15/2025

    From the encyclopedia
    PP405 →

    mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials

    Minoxidil →

    Vasodilator used on the scalp and, at low doses, as a tablet

    Finasteride →

    Popular 5-alpha reductase inhibitor that lowers DHT, taken as a pill or used topically

    At a glance
    In this educational post, the primary subjects mentioned are
    💧 PP405 (topical) nightly 4 weeks
    💧 Minoxidil (topical) 2x daily
    💊 Finasteride (oral)
    the tone is 😀 positive with impressive results.

    Other terms

    PP405 is a promising new hair loss treatment that may reactivate dormant hair follicles without side effects. It could surpass traditional treatments like minoxidil and finasteride if successful in further trials.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

      community PP405: The Ultimate Hair Loss Drug for Complete Hair Growth

       211 upvotes 1 year ago
      PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

      community Can we get a reality check on PP405?

       79 upvotes 11 months ago
      PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

      community If PP405 works it will be fkn impossible to buy it.

       103 upvotes 10 months ago
      PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.

    Related Research

    6 / 6 results

      research PP405 in Alopecia: An Emerging Molecule worth Investigating

      January 2026 in “Journal of Community Medicine and Health Solutions”
      In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.

      research Recent Advances in Drug Development for Hair Loss

      April 2025 in “International Journal of Molecular Sciences”
      This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.

      research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique

      March 2025 in “HAL (Le Centre pour la Communication Scientifique Directe)”
      This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.

      research Eosinophilic Folliculitis in a Dog

      January 2021 in “ACTA SCIENTIAE VETERINARIAE”
      This case report describes a 1-year-old Daschund with canine eosinophilic folliculitis whose symptoms improved following immunosuppressive therapy with glucocorticoids.